Biogen (BIIB)
(Delayed Data from NSDQ)
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View
by Zacks Equity Research
The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.
Top Research Reports for February 28, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Visa (V) and Biogen (BIIB).
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib
by Arpita Dutt
Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.
The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean
Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
Biogen (BIIB) Beats on Q4 Earnings; Misses Sales
by Zacks Equity Research
BIIB???s fourth quarter 2016 earnings were better-than expected. The company posted earnings of $5.04 per share while our consensus called for EPS of $4.97.
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA
by Zacks Equity Research
Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.
Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY
by Zacks Equity Research
How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?
Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
by Zacks Equity Research
Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.
The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway
Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit
by Zacks Equity Research
Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
by Zacks Equity Research
Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.
Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
by Zacks Equity Research
We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.
The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal
Biogen (BIIB) Presents Positive Phase III Data on Spinraza
by Zacks Equity Research
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
by Arpita Dutt
Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
by Zacks Equity Research
Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
AbbVie's Humira and Imbruvica Drive Performance in 2016
by Zacks Equity Research
AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.
Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold
by Arpita Dutt
Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.
Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.